Selpercatinib Patent Expiration
Selpercatinib is Used for treating advanced or metastatic thyroid cancer and non-small cell lung cancer with specific genetic mutations that are refractory to other treatments. It was first introduced by Loxo Oncology Inc A Wholly Owned Sub Of Eli Lilly And Co
Selpercatinib Patents
Given below is the list of patents protecting Selpercatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Retevmo | US10584124 | Crystalline forms | Oct 10, 2038 | Loxo Oncol Eli Lilly |
| Retevmo | US10584124 | Crystalline forms | Oct 10, 2038 | Loxo Oncol Eli Lilly |
| Retevmo | US10786489 | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile | Oct 10, 2038 | Loxo Oncol Eli Lilly |
| Retevmo | US10786489 | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile | Oct 10, 2038 | Loxo Oncol Eli Lilly |
| Retevmo | US10112942 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Oct 10, 2037 | Loxo Oncol Eli Lilly |
| Retevmo | US10112942 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Oct 10, 2037 | Loxo Oncol Eli Lilly |
| Retevmo | US10137124 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Oct 10, 2037 | Loxo Oncol Eli Lilly |
| Retevmo | US10137124 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Oct 10, 2037 | Loxo Oncol Eli Lilly |
| Retevmo | US10172851 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Oct 10, 2037 | Loxo Oncol Eli Lilly |
| Retevmo | US10172851 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Oct 10, 2037 | Loxo Oncol Eli Lilly |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Selpercatinib's patents.
Latest Legal Activities on Selpercatinib's Patents
Given below is the list recent legal activities going on the following patents of Selpercatinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 21 Feb, 2024 | US10786489 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Aug, 2023 | US10584124 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jun, 2022 | US10172851 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Apr, 2022 | US10137124 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Mar, 2022 | US10112942 |
| Post Issue Communication - Certificate of Correction | 25 Nov, 2020 | US10786489 |
| Sequence Moved to Public Database | 29 Sep, 2020 | US10786489 |
| Recordation of Patent Grant Mailed Critical | 29 Sep, 2020 | US10786489 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Sep, 2020 | US10786489 |
| Email Notification Critical | 15 Sep, 2020 | US10786489 |
Selpercatinib's Family Patents
